vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Thermon Group Holdings, Inc. (THR). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $147.3M, roughly 1.3× Thermon Group Holdings, Inc.). Thermon Group Holdings, Inc. runs the higher net margin — 12.4% vs -14.6%, a 27.0% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 9.6%). Thermon Group Holdings, Inc. produced more free cash flow last quarter ($13.1M vs $-18.7M).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Thermon Group Holdings, Inc. is a global provider of engineered thermal management solutions, specializing in heat tracing systems, heating cables, temperature monitoring controls, and associated installation support services. It serves core industrial segments including oil and gas, chemical processing, power generation, and food and beverage, with operating bases across North America, Europe, Asia-Pacific, and Latin America.
AXSM vs THR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $147.3M |
| Net Profit | $-28.6M | $18.3M |
| Gross Margin | — | 46.6% |
| Operating Margin | -13.8% | 18.1% |
| Net Margin | -14.6% | 12.4% |
| Revenue YoY | 65.0% | 9.6% |
| Net Profit YoY | 61.9% | -1.3% |
| EPS (diluted) | $-0.55 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $147.3M | ||
| Q3 25 | $171.0M | $131.7M | ||
| Q2 25 | $150.0M | $108.9M | ||
| Q1 25 | $121.5M | — | ||
| Q4 24 | $118.8M | — | ||
| Q3 24 | $104.8M | — | ||
| Q2 24 | $87.2M | — | ||
| Q1 24 | $75.0M | — |
| Q4 25 | $-28.6M | $18.3M | ||
| Q3 25 | $-47.2M | $15.0M | ||
| Q2 25 | $-48.0M | $8.6M | ||
| Q1 25 | $-59.4M | — | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | — | ||
| Q2 24 | $-79.3M | — | ||
| Q1 24 | $-68.4M | — |
| Q4 25 | — | 46.6% | ||
| Q3 25 | — | 46.4% | ||
| Q2 25 | — | 44.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -13.8% | 18.1% | ||
| Q3 25 | -27.0% | 16.4% | ||
| Q2 25 | -24.5% | 10.8% | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | — | ||
| Q2 24 | -89.5% | — | ||
| Q1 24 | -89.7% | — |
| Q4 25 | -14.6% | 12.4% | ||
| Q3 25 | -27.6% | 11.4% | ||
| Q2 25 | -32.0% | 7.9% | ||
| Q1 25 | -48.9% | — | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | — | ||
| Q2 24 | -91.0% | — | ||
| Q1 24 | -91.1% | — |
| Q4 25 | $-0.55 | $0.55 | ||
| Q3 25 | $-0.94 | $0.45 | ||
| Q2 25 | $-0.97 | $0.26 | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-1.67 | — | ||
| Q1 24 | $-1.44 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $46.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $538.7M |
| Total Assets | $689.8M | $816.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $46.9M | ||
| Q3 25 | $325.3M | $29.7M | ||
| Q2 25 | $303.0M | $36.5M | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — | ||
| Q1 24 | $331.4M | — |
| Q4 25 | $88.3M | $538.7M | ||
| Q3 25 | $73.7M | $515.2M | ||
| Q2 25 | $73.1M | $509.3M | ||
| Q1 25 | $53.2M | — | ||
| Q4 24 | $57.0M | — | ||
| Q3 24 | $92.9M | — | ||
| Q2 24 | $102.9M | — | ||
| Q1 24 | $144.0M | — |
| Q4 25 | $689.8M | $816.7M | ||
| Q3 25 | $669.3M | $778.2M | ||
| Q2 25 | $639.8M | $765.3M | ||
| Q1 25 | $596.7M | — | ||
| Q4 24 | $568.5M | — | ||
| Q3 24 | $561.5M | — | ||
| Q2 24 | $548.2M | — | ||
| Q1 24 | $545.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $18.0M |
| Free Cash FlowOCF − Capex | $-18.7M | $13.1M |
| FCF MarginFCF / Revenue | -9.6% | 8.9% |
| Capex IntensityCapex / Revenue | 0.0% | 3.3% |
| Cash ConversionOCF / Net Profit | — | 0.98× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $18.0M | ||
| Q3 25 | $1.0M | $7.4M | ||
| Q2 25 | $-32.4M | $10.7M | ||
| Q1 25 | $-43.4M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.6M | — | ||
| Q2 24 | $-30.1M | — | ||
| Q1 24 | $-53.5M | — |
| Q4 25 | $-18.7M | $13.1M | ||
| Q3 25 | $988.0K | $4.4M | ||
| Q2 25 | $-32.4M | $8.3M | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-53.6M | — |
| Q4 25 | -9.6% | 8.9% | ||
| Q3 25 | 0.6% | 3.3% | ||
| Q2 25 | -21.6% | 7.6% | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — | ||
| Q1 24 | -71.4% | — |
| Q4 25 | 0.0% | 3.3% | ||
| Q3 25 | 0.0% | 2.3% | ||
| Q2 25 | 0.0% | 2.2% | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 0.98× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
THR
| Other | $73.7M | 50% |
| Transferred At Point In Time | $56.1M | 38% |
| Transferred Over Time | $17.5M | 12% |
